OBJECTIVES Metformin therapy has previously been associated with reduced abdominal aortic aneurysm growth rate in diabetic patients and shown to suppress the formation and progression of abdominal aortic aneurysm in normoglycemic mice. Here, we investigated the association between Metformin treatment and prevalence of aneurysm in the ascending aorta (AscAA). METHODS A total of 734 patients undergoing open-heart surgery for AscAA and/or aortic valve disease were studied. Diabetes status and medication use were self-reported by the patients in a systematic questionnaire. Aortic dilatation was defined as an aortic root or ascending aortic diameter ≥4.0 cm. High-sensitivity C-reactive protein levels were assessed as a measure of systemic inflammation. RESULTS We could confirm the inverse association between diabetes and AscAA prevalence (16% vs 43.9%, for diabetic and non-diabetic patients, respectively; Odds ratio 0.243; 95% CI, 0.129–0.460, P < 0.001). Furthermore, in diabetic patients, Metformin treatment was associated with lower high-sensitivity C-reactive protein levels. There was, however, no difference in the prevalence of AscAA among diabetic patients with and without Metformin treatment (16% vs 16% for treated and non-treated patients, respectively; OR 1.039; 95% CI 0.26–4.19, P = 0.957). CONCLUSIONS Our data do not support a protective effect of Metformin therapy in AscAA formation. Subj collection 161, 173

中文翻译：

---

二甲双胍治疗与糖尿病患者升主动脉瘤的较低患病率无关

目标二甲双胍治疗以前与糖尿病患者腹主动脉瘤生长率降低有关，并显示抑制血糖正常小鼠腹主动脉瘤的形成和进展。在这里，我们调查了二甲双胍治疗与升主动脉 (AscAA) 动脉瘤患病率之间的关联。方法共研究了 734 名因 AscAA 和/或主动脉瓣疾病而接受心脏直视手术的患者。糖尿病状态和药物使用由患者在系统问卷中自我报告。主动脉扩张定义为主动脉根部或升主动脉直径≥4.0 cm。高敏 C 反应蛋白水平被评估为全身炎症的量度。结果 我们可以确认糖尿病与 AscAA 患病率之间的负相关（16% vs 43.9%，分别用于糖尿病和非糖尿病患者；优势比 0.243；95% CI，0.129–0.460，P < 0.001)。此外，在糖尿病患者中，二甲双胍治疗与较低的高敏 C 反应蛋白水平相关。然而，接受和不接受二甲双胍治疗的糖尿病患者的 AscAA 患病率没有差异（治疗和未治疗的患者分别为 16% 和 16%；OR 1.039；95% CI 0.26–4.19，P = 0.957） . 结论 我们的数据不支持二甲双胍治疗对 AscAA 形成的保护作用。主题集合 161, 173 接受和不接受二甲双胍治疗的糖尿病患者中，AscAA 的患病率没有差异（治疗和未治疗的患者分别为 16% 和 16%；OR 1.039；95% CI 0.26–4.19，P = 0.957）。结论 我们的数据不支持二甲双胍治疗对 AscAA 形成的保护作用。主题集合 161, 173 接受和不接受二甲双胍治疗的糖尿病患者中，AscAA 的患病率没有差异（治疗和未治疗的患者分别为 16% 和 16%；OR 1.039；95% CI 0.26–4.19，P = 0.957）。结论 我们的数据不支持二甲双胍治疗对 AscAA 形成的保护作用。主题集合 161, 173